FHD-286
FHD-286-C-002
Phase 1 small_molecule active
Quick answer
FHD-286 for Advanced Hematologic Malignancy is a Phase 1 program (small_molecule) at Foghorn Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Foghorn Therapeutics
- Indication
- Advanced Hematologic Malignancy
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active